Tech Center 1600 • Art Units: 1654 1658 1675 1676
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17848736 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18534086 | SYNTHETIC DNA BINDING DOMAIN PEPTIDES AND USES THEREOF | Non-Final OA | The University of Chicago |
| 19329427 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | Non-Final OA | Ohio State Innovation Foundation |
| 18644750 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | Non-Final OA | Ohio State Innovation Foundation |
| 17778138 | PENTAPEPTIDE AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 19020677 | PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER | Final Rejection | Jubilant Draximage Inc. |
| 17675910 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17946816 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASE USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18903801 | REGENERATIVE PEPTIDES AND METHODS FOR USE THEREOF | Final Rejection | Animate Biosciences, Inc. |
| 17996917 | LIPID-PEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17828609 | Mitochondria-Targeted Polypeptide, Preparation Method thereof, and Use thereof | Non-Final OA | SUN YAT-SEN UNIVERSITY |
| 17698433 | SATIATION PEPTIDES FOR WEIGHT LOSS AND ALTERED TASTE SENSITIVITY | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17781438 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Non-Final OA | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD. |
| 17781543 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | Non-Final OA | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD. |
| 18008771 | DOCK TAG SYSTEM | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18433336 | METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES | Final Rejection | Larimar Therapeutics, Inc. |
| 18262113 | USE OF LINK-TSG6 FOR THE TREATMENT OF OSTEOARTHRITIC PAIN | Non-Final OA | The University of Manchester |
| 18018518 | BROAD-SPECTRUM ANTIVIRAL DRUG FOR ENTEROVIRUS, AND APPLICATION | Non-Final OA | WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES |
| 17642505 | IMAGING AND THERAPEUTIC COMPOSITIONS | Final Rejection | The University of Melbourne |
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | Non-Final OA | NXERA PHARMA UK LIMITED |
| 18554737 | ENGINEERING PEPTIDES FOR A A VB6 INTEGRIN BINDING AND RELATED METHODS OF USE AND SYNTHESIS | Non-Final OA | Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
| 18285203 | CONJUGATED HEPCIDIN MIMETICS | Non-Final OA | Protagonist Therapeutics, Inc. |
| 18283376 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | Non-Final OA | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases |
| 18550536 | ANTI-INFLAMMATORY PEPTIDE AND METHOD OF USE THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 17995097 | VIPR2 ANTAGONIST PEPTIDE | Non-Final OA | ICHIMARU PHARCOS CO., LTD |
| 17839323 | TOPICAL CYCLOSPORINE FOR TREATING PSORIASIS AND OTHER AILMENTS | Non-Final OA | Dyve Biosciences, Inc. |
| 17267652 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Non-Final OA | LUBRIZOL ADVANCED MATERIALS, INC. |
| 18039130 | BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | Non-Final OA | D&D Pharmatech Inc. |
| 18038936 | ADHESIVE PEPTIDES | Final Rejection | Zentraxa Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy